LEO Pharma
Industriparken 55
DK-2750 Ballerup
Copenhagen
Tel: 45-4492-3800
Fax: 45-4494-3040
Website: http://www.leo-pharma.com/
Email: leo.group@leo-pharma.com
121 articles with LEO Pharma
-
Genoskin’s solution is to develop the technologies to replace animals and humans in clinical studies with virtual models, steadily pushing living creatures further and further from testing.
-
Tralokinumab Achieves Primary and Secondary Endpoints in Phase 3 Trial of Adolescents With Moderate-to-Severe Atopic Dermatitis
10/22/2021
LEO Pharma A/S today announced 16-week results of a 52-week monotherapy trial showing tralokinumab significantly improved primary and secondary measurements of efficacy among adolescents (aged 12 to 17) with moderate-to-severe atopic dermatitis.
-
Skin health logged major wins this week after two companies announced positive clinical trial results.
-
The Product Monograph for Protopic® has been updated
10/4/2021
LEO Pharma Inc. announced that Health Canada has approved an update to the Product Monograph of Protopic®, removing the Serious Warnings and Precautions box, also referred to as a boxed warning, regarding a potential association with the use of topical calcineurin inhibitors and malignancy.
-
It was a busy week for clinical trial news. Here’s a look.
-
LEO Pharma presents interim data from Phase 3 tralokinumab long-term extension trial in moderate-to-severe atopic dermatitis at EADV 30th Congress
9/30/2021
LEO Pharma A/S announced results showing adult patients with moderate-to-severe atopic dermatitis maintained improvements in signs and symptoms, itch severity and sleep interference following two years of continuous treatment with tralokinumab.1 Interim findings from the Phase 3 ECZTEND trial were shared as an oral presentation during the European Academy of Dermatology and Venereology Congress 2021.
-
LEO Pharma and Veeva Systems Partner for Patient-centric Digital Trials
9/29/2021
LEO Pharma , a global leader in medical dermatology, and Veeva Systems (NYSE: VEEV) today announced a strategic technology partnership to enable scalable digital trials that are patient-centric and paperless.
-
The U.S. FDA has released a Complete Response Letter (CRL) following its review of LEO Pharma’s tralokinumab. Further data on a device component is the issue brought to light by the recently completed Biologics License Application (BLA) review.
-
LEO Pharma to Highlight New Data in Medical Dermatology at EADV Virtual 2020
10/27/2020
LEO Pharma Inc. today announced that data from across its dermatology portfolio of approved and investigational medicines will be presented at the 29th Congress of the European Academy of Dermatology and Venereology (EADV), Vienna, Oct. 29-31, 2020. EADV’s 29th Congress will be fully virtual.
-
LEO Pharma Announces British Journal of Dermatology Publication of Three Pivotal Ph 3 Trials of Tralokinumab
10/16/2020
LEO Pharma Inc., a global leader in medical dermatology, today announced that the British Journal of Dermatology has published primary data from the pivotal ECZTRA 1, 2 and ECZTRA 3 Phase 3 trials of tralokinumab in adult patients with moderate-to-severe atopic dermatitis (AD).
-
UNION therapeutics announces acquisition of PDE4i compound class from LEO Pharma with oral lead candidate (orismilast) in Phase 2
7/21/2020
Candidates in the LEO PDE4 inhibitor compound series have demonstrated potential to become `best-in-class' based on Phase 2 studies in psoriasis (oral) and atopic dermatitis (topical)
-
Kubota Vision Announces Signing of Open Innovation Agreement with LEO Pharma A/S to Screen Novel VAP-1 Inhibitor Compounds for Inflammatory Skin Diseases
4/16/2020
Kubota Vision Inc., formerly known as Acucela Inc., a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., announced the signing of an Open Innovation Agreement with LEO Pharma A/S to screen novel Vascular Adhesion Protein-1 inhibitor compounds discovered by Kubota Vision.
-
BioSpace Global Roundup, April 16
4/16/2020
Global pharma and life sciences companies provide updates on their business operations and pipelines. -
The future of the atopic dermatitis space is going to be a competitive one. Multiple assets are in line to be submitted for regulatory approval and will, if approved, challenge the leading market share currently held by Regeneron and Sanofi’s Dupixent.
-
LEO Pharma and Portal Instruments Announce Collaboration to Develop Needle-Free Drug Delivery Device
12/4/2019
LEO Pharma A/S and Portal Instruments announced a global collaboration and license agreement to develop Portal’s innovative needle-free drug delivery system for use in combination with LEO Pharma’s portfolio of investigational and approved medicines.
-
LEO Pharma announces agreement with Ubiquigent to access novel compounds
10/30/2019
Ubiquigent Limited and LEO Pharma A/S announced that they have entered into an option agreement granting LEO Pharma access to two novel compounds.
-
LEO Pharma Enters Into Option Agreement With Ubiquigent for Access to Novel Compounds
10/30/2019
Ubiquigent Limited and LEO Pharma A/S announced that they have entered into an option agreement granting LEO Pharma access to two novel compounds.
-
LEO Pharma Files IND Application to FDA for a Clinical Study of JW1601/LP0190 in the US
8/27/2019
Based on the successfully completed single-dose part of the phase I clinical trial in Korean population carried out by JW Pharmaceutical, LEO Pharma files IND application to the FDA for study of JW1601/LP0190 in US set to start in 2020.
-
LEO Pharma A/S Acquires Rights to Develop and Market brodalumab for Moderate-to-Severe Psoriasis Outside of Europe
8/13/2019
New sub-licensing agreement allows LEO Pharma to help more people around the world with an additional treatment option for psoriasis
-
LEO Pharma Inc. Announces U.S. Food and Drug Administration (FDA) Expanded Regulatory Approvals for Enstilar® Foam and Taclonex® Topical Suspension in Treatment of Plaque Psoriasis
7/31/2019
LEO Pharma Inc., a wholly owned subsidiary of LEO Pharma A/S, announced today the U.S. Food and Drug Administration (FDA) has expanded the approved indication for Enstilar® (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064%, for the topical treatment of plaque psoriasis to include patients age 12 and older.